The effect of sacral neuromodulation on pudendal nerve function and female sexual function

Brent A Parnell, James F. Howard, Elizabeth J. Geller

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Aims: To quantify changes in pudendal nerve function with sacral neuromodulation (SNM). To understand the relationship of pudendal nerve function to SNM treatment response for overactive bladder. To assess the relationship between female sexual function and pudendal nerve function after SNM. Methods: Women undergoing SNM between January 2010 and May 2011 were enrolled. Baseline pudendal nerve terminal motor latencies (PNTML) were measured bilaterally. Subjects underwent peripheral nerve evaluation (PNE) prior to SNM therapy. PNTML was measured at 1 and 6 weeks after sacral neuromodulator implant. Women who did not undergo permanent implantation were reassessed at the end of the 1-week PNE testing phase. Pelvic floor and sexual function questionnaires were administered at baseline and follow-up to assess pelvic floor and sexual function. Results: Of 34 women enrolled, 31 were evaluated. Mean age was 67.4 ± 14.2 years with 29/34 (85.3%) treated for refractory overactive bladder. Thirty of 31 (96.7%) went on to a permanent implant. PNE success rate was 73.5% (25/33). Mean PNTML changed from 2.74 ± 0.52 msec at baseline to 2.57 ± 0.50 msec at 6 weeks postop (P = 0.198). Baseline amplitude remained stable at 1 and 6 weeks. At 6 weeks PISQ-12 scores showed improved sexual function (P < 0.034) and PFDI-20 and PFIQ-7 scores showed improved pelvic floor, colorectal and urinary symptoms (P < 0.05). Conclusions: Women with refractory overactive bladder and non-obstructive urinary retention have abnormal pudendal nerve function, which showed a non-significant trend toward improvement after SNM. Sexually active women undergoing sacral neuromodulation experienced improvement in sexual function. Quality of life improved due to improvement in urinary and colorectal function.

Original languageEnglish (US)
Pages (from-to)456-460
Number of pages5
JournalNeurourology and Urodynamics
Volume34
Issue number5
DOIs
StatePublished - Jun 1 2015

Fingerprint

Pudendal Nerve
Overactive Urinary Bladder
Pelvic Floor
Peripheral Nerves
Urinary Retention
Neurotransmitter Agents
Quality of Life
Therapeutics

Keywords

  • Pudendal nerve terminal motor latencies
  • Quality of life
  • Sacral neuromodulation
  • Sexual function
  • Urinary incontinence
  • Urinary retention

ASJC Scopus subject areas

  • Clinical Neurology
  • Urology

Cite this

The effect of sacral neuromodulation on pudendal nerve function and female sexual function. / Parnell, Brent A; Howard, James F.; Geller, Elizabeth J.

In: Neurourology and Urodynamics, Vol. 34, No. 5, 01.06.2015, p. 456-460.

Research output: Contribution to journalArticle

Parnell, Brent A ; Howard, James F. ; Geller, Elizabeth J. / The effect of sacral neuromodulation on pudendal nerve function and female sexual function. In: Neurourology and Urodynamics. 2015 ; Vol. 34, No. 5. pp. 456-460.
@article{dc79595564bc4efa94761b7ff78673c5,
title = "The effect of sacral neuromodulation on pudendal nerve function and female sexual function",
abstract = "Aims: To quantify changes in pudendal nerve function with sacral neuromodulation (SNM). To understand the relationship of pudendal nerve function to SNM treatment response for overactive bladder. To assess the relationship between female sexual function and pudendal nerve function after SNM. Methods: Women undergoing SNM between January 2010 and May 2011 were enrolled. Baseline pudendal nerve terminal motor latencies (PNTML) were measured bilaterally. Subjects underwent peripheral nerve evaluation (PNE) prior to SNM therapy. PNTML was measured at 1 and 6 weeks after sacral neuromodulator implant. Women who did not undergo permanent implantation were reassessed at the end of the 1-week PNE testing phase. Pelvic floor and sexual function questionnaires were administered at baseline and follow-up to assess pelvic floor and sexual function. Results: Of 34 women enrolled, 31 were evaluated. Mean age was 67.4 ± 14.2 years with 29/34 (85.3{\%}) treated for refractory overactive bladder. Thirty of 31 (96.7{\%}) went on to a permanent implant. PNE success rate was 73.5{\%} (25/33). Mean PNTML changed from 2.74 ± 0.52 msec at baseline to 2.57 ± 0.50 msec at 6 weeks postop (P = 0.198). Baseline amplitude remained stable at 1 and 6 weeks. At 6 weeks PISQ-12 scores showed improved sexual function (P < 0.034) and PFDI-20 and PFIQ-7 scores showed improved pelvic floor, colorectal and urinary symptoms (P < 0.05). Conclusions: Women with refractory overactive bladder and non-obstructive urinary retention have abnormal pudendal nerve function, which showed a non-significant trend toward improvement after SNM. Sexually active women undergoing sacral neuromodulation experienced improvement in sexual function. Quality of life improved due to improvement in urinary and colorectal function.",
keywords = "Pudendal nerve terminal motor latencies, Quality of life, Sacral neuromodulation, Sexual function, Urinary incontinence, Urinary retention",
author = "Parnell, {Brent A} and Howard, {James F.} and Geller, {Elizabeth J.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1002/nau.22579",
language = "English (US)",
volume = "34",
pages = "456--460",
journal = "Neurourology and Urodynamics",
issn = "0733-2467",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - The effect of sacral neuromodulation on pudendal nerve function and female sexual function

AU - Parnell, Brent A

AU - Howard, James F.

AU - Geller, Elizabeth J.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Aims: To quantify changes in pudendal nerve function with sacral neuromodulation (SNM). To understand the relationship of pudendal nerve function to SNM treatment response for overactive bladder. To assess the relationship between female sexual function and pudendal nerve function after SNM. Methods: Women undergoing SNM between January 2010 and May 2011 were enrolled. Baseline pudendal nerve terminal motor latencies (PNTML) were measured bilaterally. Subjects underwent peripheral nerve evaluation (PNE) prior to SNM therapy. PNTML was measured at 1 and 6 weeks after sacral neuromodulator implant. Women who did not undergo permanent implantation were reassessed at the end of the 1-week PNE testing phase. Pelvic floor and sexual function questionnaires were administered at baseline and follow-up to assess pelvic floor and sexual function. Results: Of 34 women enrolled, 31 were evaluated. Mean age was 67.4 ± 14.2 years with 29/34 (85.3%) treated for refractory overactive bladder. Thirty of 31 (96.7%) went on to a permanent implant. PNE success rate was 73.5% (25/33). Mean PNTML changed from 2.74 ± 0.52 msec at baseline to 2.57 ± 0.50 msec at 6 weeks postop (P = 0.198). Baseline amplitude remained stable at 1 and 6 weeks. At 6 weeks PISQ-12 scores showed improved sexual function (P < 0.034) and PFDI-20 and PFIQ-7 scores showed improved pelvic floor, colorectal and urinary symptoms (P < 0.05). Conclusions: Women with refractory overactive bladder and non-obstructive urinary retention have abnormal pudendal nerve function, which showed a non-significant trend toward improvement after SNM. Sexually active women undergoing sacral neuromodulation experienced improvement in sexual function. Quality of life improved due to improvement in urinary and colorectal function.

AB - Aims: To quantify changes in pudendal nerve function with sacral neuromodulation (SNM). To understand the relationship of pudendal nerve function to SNM treatment response for overactive bladder. To assess the relationship between female sexual function and pudendal nerve function after SNM. Methods: Women undergoing SNM between January 2010 and May 2011 were enrolled. Baseline pudendal nerve terminal motor latencies (PNTML) were measured bilaterally. Subjects underwent peripheral nerve evaluation (PNE) prior to SNM therapy. PNTML was measured at 1 and 6 weeks after sacral neuromodulator implant. Women who did not undergo permanent implantation were reassessed at the end of the 1-week PNE testing phase. Pelvic floor and sexual function questionnaires were administered at baseline and follow-up to assess pelvic floor and sexual function. Results: Of 34 women enrolled, 31 were evaluated. Mean age was 67.4 ± 14.2 years with 29/34 (85.3%) treated for refractory overactive bladder. Thirty of 31 (96.7%) went on to a permanent implant. PNE success rate was 73.5% (25/33). Mean PNTML changed from 2.74 ± 0.52 msec at baseline to 2.57 ± 0.50 msec at 6 weeks postop (P = 0.198). Baseline amplitude remained stable at 1 and 6 weeks. At 6 weeks PISQ-12 scores showed improved sexual function (P < 0.034) and PFDI-20 and PFIQ-7 scores showed improved pelvic floor, colorectal and urinary symptoms (P < 0.05). Conclusions: Women with refractory overactive bladder and non-obstructive urinary retention have abnormal pudendal nerve function, which showed a non-significant trend toward improvement after SNM. Sexually active women undergoing sacral neuromodulation experienced improvement in sexual function. Quality of life improved due to improvement in urinary and colorectal function.

KW - Pudendal nerve terminal motor latencies

KW - Quality of life

KW - Sacral neuromodulation

KW - Sexual function

KW - Urinary incontinence

KW - Urinary retention

UR - http://www.scopus.com/inward/record.url?scp=84930871702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930871702&partnerID=8YFLogxK

U2 - 10.1002/nau.22579

DO - 10.1002/nau.22579

M3 - Article

C2 - 24615871

AN - SCOPUS:84930871702

VL - 34

SP - 456

EP - 460

JO - Neurourology and Urodynamics

JF - Neurourology and Urodynamics

SN - 0733-2467

IS - 5

ER -